We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-0.23%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$238M
AUM Growth
-$45.5M
Cap. Flow
-$26.2M
Cap. Flow %
-11.03%
Top 10 Hldgs %
62.29%
Holding
58
New
11
Increased
7
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$18.1M
2
RLMD icon
Relmada Therapeutics
RLMD
+$8.98M
3
PYXS icon
Pyxis Oncology
PYXS
+$7.76M
4
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.81M
5
VRDN icon
Viridian Therapeutics
VRDN
+$3.39M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.9M
2
BLU
BELLUS Health Inc.
BLU
+$9.84M
3
CLSD
Clearside Biomedical
CLSD
+$7.9M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.75M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.28M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Financials 5.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
51
United Therapeutics
UTHR
$22.6B
– –
-3,000
Closed -$554K
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
– –
-210,000
Closed -$1.3M
VINC
53
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-13,000
Closed -$4.2M
CBAY
54
DELISTED
Cymabay Therapeutics
CBAY
– –
-301,904
Closed -$1.1M
RAIN
55
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-182,500
Closed -$2.73M
RETA
56
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-17,500
Closed -$1.76M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Acuta Capital Partners held 58 positions worth $238M, down 16% from $283M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $26.2M in Q4 2021, closing 22 positions and reducing 11 holdings. Its most notable exit was Clearside Biomedical, an estimated $7.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Relmada Therapeutics worth $9.1M.

  • Acuta Capital Partners's largest Q4 2021 buy was Relmada Therapeutics: 404,000 shares worth $9.1M.
  • Acuta Capital Partners added most to Apellis Pharmaceuticals in Q4 2021, an estimated $18.1M increase.
  • Acuta Capital Partners's biggest Q4 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $10.9M.
  • Acuta Capital Partners fully exited Clearside Biomedical in Q4 2021, selling an estimated $7.9M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $238M portfolio in Q4 2021.
  • Acuta Capital Partners opened 11 new positions and closed 22 in Q4 2021.
  • Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $238M.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.